Nonalcoholic steatohepatitis

Gastroenterology

Volumn 121, Issue 3, 2001, Pages 710-723

  Reid, Andrea E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL FEATURE; DISEASE COURSE; HEPATITIS; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; LIPID PEROXIDATION; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0034831067     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.27126     Document Type: Article

References (116)

1. Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease
2. Clinical hepatology: Profile of an urban, hospital-based practice
3. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis
4. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients
5. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
6. Steatohepatitis in obese children: A cause of chronic liver dysfunction
7. Idiopathic steatohepatitis in childhood: A multicenter retrospective study
8. Nonalcoholic steatohepatitis: An expanded clinical entity
9. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
10. Nonalcoholic steatohepatitis: A study of 49 patients
11. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
12. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
13. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
14. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
15. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis
16. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
17. Fatty liver hepatitis and cirrhosis in obese patients
18. Liver pathology in morbidly obese patients with and without diabetes
19. Hepatic morphology in obesity
20. Liver in obesity
21. Insulin resistance-associated hepatic iron overload
22. Body fat topography as an independent predictor of fatty liver
23. Pathophysiology and pathogenesis of visceral fat obesity
24. Liver disturbances in obesity and diabetes mellitus
25. Association of nonalcoholic fatty liver disease with insulin resistance
26. Non-alcoholic fatty liver: Another feature of the metabolic syndrome?
27. An epilogue to jejunoileal bypass
28. A 13-year review of jejunoileal bypass
29. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion
30. Severe hepatocellular reaction resembling alcoholic hepatitis with cirrhosis after massive small bowel resection and prolonged total parenteral nutrition
31. Liver injury with alcoholic-like hyalin after gastroplasty for morbid obesity
32. Hepatobiliary abnormalities associated with total parenteral nutrition
33. Hepatic complications of total parenteral nutrition
34. Steatohepatitis associated with limb lipodystrophy
35. Alcoholic hyalins (Mallory bodies) in a case of Weber-Christian disease: Electron microscopic observations of liver involvement
36. Nonalcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth
37. Liver ultrastructure in abetalipoproteinemia: Evolution of micronodular cirrhosis
38. Drug-induced liver disease
39. Amiodarone hepatotoxicity simulating alcoholic liver disease
40. Perhexilene maleate-induced cirrhosis
41. Cirrhosis with steatohepatitis after adjuvant tamoxifen
42. Tamoxifen-induced steatohepatitis
43. Tamoxifen-induced steatohepatitis
44. Isoniazid and nonalcoholic steatohepatitis
45. "Nonalcoholic steatohepatitis" induced by massive doses of synthetic estrogen
46. Nonalcoholic steatohepatitis: A toxic liver disease in industrial workers
47. Nonalcoholic steatohepatitis
48. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury
49. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients
50. Liver fibrosis in overweight patients
51. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis
52. Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis
53. Hepatic iron and nonalcoholic fatty liver disease
54. Nonalcoholic steatohepatitis: Tightening the morphological screws on a hepatic rambler
55. Hepatic steatosis and lipid peroxidation in human chronic liver diseases
56. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
57. Nonalcoholic steatohepatitis
58. Fatty Liver
59. Metabolic and nutritional considerations in nonalcoholic fatty liver
60. Protein-calorie malnutrition and the liver
61. Regulation of hepatic fatty acid oxidation and ketone body production
62. Free radicals in the pathogenesis of kwashiorkor
63. Studies on hepatic and extrahepatic lipoprotein lipases in protein-calorie malnutrition
64. Pathogenesis of hepatic steatosis in the parenterally fed rat
65. The role of factors that regulate the synthesis and secretion of very-low-density lipoprotein by hepatocytes
66. Hepatic steatosis after intestinal bypass - Prevention and reversal by metronidazole irrespective of protein-calorie malnutrition
67. Steatohepatitis: A tale of two "hits"?
68. Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA
69. Ethanol-inducible cytochrome P-450 2E1: Genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease
70. Lipid peroxidation dependent on ethanol-inducible cytochrome P-450 from rat liver
71. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation
72. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
73. Effects of fatty acids and ketone bodies on cytochromes P4502B, 4A, and 2E1 expression in primary cultured rat hepatocytes
74. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes
75. Homeostasis model assessment: Insulin resistance and B-cell function from plasma fasting glucose and insulin concentrations in man
76. Fatty liver - An additional and treatable feature of the insulin resistance syndrome
77. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis
78. Metabolic aspects of peroxisomal b-oxidation
79. The pathology of hepatic iron overload: A free radical-mediated process?
80. Hepatic mitochondrial energy production in rats with chronic iron overload
81. Enhanced hepatic collagen type 1 mRNA expression into fat-storing cells in a rodent model of hemochromatosis
82. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies
83. Iron and fibrosis in nonalcoholic fatty liver disease
84. NASH: Can we iron out the pathogenesis?
85. Cytokines and alcoholic liver disease
86. Prognostic indicators of hepatic injury following jejunoileal bypass performed for refractory obesity: A prospective study
87. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis
88. Mitochondrial adaptations to obesity-related oxidant stress
89. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver
90. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion
91. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis - A pilot study
92. Hepatic steatosis: Innocent bystander or guilty party?
93. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis
94. Natural history of alcoholic hepatitis II. The long term prognosis
95. Prognosis in nonalcoholic steatohepatitis
96. The natural history of nonalcoholic fatty liver: A follow-up study
97. Ultrasound scanning in the detection of hepatic fibrosis and steatosis
98. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease
99. Conventional and coming laboratory markers of alcoholism and heavy drinking
100. Serum mitochondrial asparate aminotransferase as a marker of chronic alcoholism: Diagnostic value and interpretation in a liver unit
101. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: An aid to diagnosis
102. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?
103. Persistent hyperaminotransferasemia resolving after weight reduction in obese children
104. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting
105. Nonalcoholic steatohepatitis in obesity: A reversible condition
106. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity
107. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small-bowel bypass
108. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
109. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
110. Betaine for the treatment of nonalcoholic steatohepatitis
111. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
112. Metformin reverses fatty liver disease in obese, leptin-deficient mice
113. Pilot study of troglitazone (Rezulin) for nonalcoholic steatohepatitis
114. Recurrence of nonalcoholic steatohepatitis following liver transplantation
115. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient
116. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation